What is the recommended dosing for Effexor (venlafaxine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Effexor (Venlafaxine) Dosing

Start venlafaxine at 75 mg/day divided into 2-3 doses with food, and increase by up to 75 mg every 4 days as needed, with most patients responding to 150-225 mg/day and a maximum dose of 375 mg/day for severe or treatment-resistant depression. 1

Initial Dosing

  • Begin with 75 mg/day administered in two or three divided doses, taken with food 1
  • This starting dose applies to standard immediate-release formulations 1

Dose Titration

  • Increase the dose in increments of up to 75 mg/day at intervals of no less than 4 days based on tolerability and clinical response 1
  • The dose may be increased to 150 mg/day, and if needed, further increased up to 225 mg/day 1
  • For neuropathic pain specifically, allow 2-4 weeks to titrate to an efficacious dosage 2

Target Therapeutic Doses

  • For moderately depressed outpatients: 150-225 mg/day is typically effective, with no evidence of additional benefit beyond 225 mg/day in this population 1
  • For more severely depressed inpatients: higher doses up to 350-375 mg/day (mean 350 mg/day) may be necessary, generally administered in three divided doses 1
  • For neuropathic pain: the efficacious range is 150-225 mg/day, with a minimum effective dose of 75 mg/day 2

Maximum Dose

  • The maximum recommended dose is 375 mg/day 1
  • High-dose venlafaxine (≥375 mg/day, up to 600 mg/day) has been used in clinical practice for treatment-resistant depression, though this exceeds standard recommendations 2, 3

Special Population Adjustments

Hepatic Impairment

  • Reduce the total daily dose by 50% in patients with mild to moderate hepatic impairment 1
  • Individual variability may require even greater dose reductions in some patients with cirrhosis 1

Renal Impairment

  • Reduce the total daily dose by 25% in patients with mild to moderate renal impairment (GFR 10-70 mL/min) 1
  • Reduce the total daily dose by 50% in patients undergoing hemodialysis 1

Elderly Patients

  • No specific dose adjustment is required based on age alone 1
  • Exercise caution and use extra care when increasing doses in elderly patients 1

CYP2D6 Poor Metabolizers

  • Consider switching to an alternative antidepressant rather than dose reduction, as poor metabolizers have significantly reduced clearance and higher risk of adverse effects 2

Important Safety Monitoring

  • Monitor blood pressure, particularly at higher doses (>200 mg/day), as venlafaxine can cause modest increases in blood pressure 2
  • Blood pressure elevation occurred in 3-5% of patients receiving ≤200 mg/day, 7% receiving 201-300 mg/day, and 13% receiving >300 mg/day 4
  • Exercise caution in patients with cardiac disease due to rare reports of cardiac conduction abnormalities 2

Discontinuation Protocol

  • Taper venlafaxine gradually over 10-14 days rather than stopping abruptly to minimize withdrawal symptoms 2
  • If intolerable symptoms occur during tapering, resume the previous dose and decrease more gradually 1
  • A withdrawal syndrome can occur with abrupt discontinuation 2

MAOI Interactions

  • Allow at least 14 days between discontinuing an MAOI and starting venlafaxine 1
  • Allow at least 7 days after stopping venlafaxine before starting an MAOI 1

Common Pitfalls to Avoid

  • Avoid increasing doses too rapidly (respect the minimum 4-day interval between increases) 1
  • Don't overlook blood pressure monitoring, especially when using doses above 200 mg/day 2, 4
  • Don't abruptly discontinue—always taper to prevent withdrawal syndrome 2
  • In patients with hepatic or renal impairment, failure to reduce the dose appropriately increases risk of adverse effects 1

References

Guideline

Dose-Response Relationship and Safety Considerations for Venlafaxine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Tolerability of high-dose venlafaxine in depressed patients.

Journal of psychopharmacology (Oxford, England), 2004

Research

The role of venlafaxine in rational antidepressant therapy.

The Journal of clinical psychiatry, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.